Insight Medbotics, an interventional oncology company advancing precision in cancer care through its MRI-compatible robotics, is pleased to welcome Dr. Preston Sprenkle, an Associate Professor of Urology at Yale University, to the company’s clinical advisory board.
On September 17, Insight Medbotics previewed a new product direction for its next-generation robotics system. Glenn™ is being designed to help urologists to treat prostate cancer within an MRI scanner. It also leverages the company’s previous work on MRI-compatible and clinically demonstrated robotics in breast biopsy, the only robotics system designed for use with MRI scanners to receive 510(k) clearance from the FDA. Glenn aims to integrate hardware with the digitization of an entire care pathway, offering new data-driven clinical insight in ways that haven’t been possible before since it allows urologists intuitive MRI access while removing the guesswork of traditional ultrasound guidance.
To support this new product direction, Insight Medbotics has spent the past year recruiting several leading urologists to its clinical advisory board, and appointed Dr. Edward Matsumoto to its Board of Directors.
"I’m excited about Insight Medbotics’s approach to MRI robotics and see potential for its increasing urologic involvement in MRI-guided interventions. This is an appropriate vision for where the field is going, and will facilitate planning for biopsy and treatment,” said Dr. Sprenkle.
Dr. Sprenkle has dedicated his career to using the latest technologies to improve prostate cancer diagnosis and treatment. He is also a pioneer in “focal therapy,” which allows a surgeon to treat tiny prostate lesions, rather than the whole organ. This clinical approach avoids many of the side effects—such as erectile dysfunction and urinary incontinence—that may follow removing the whole prostate. His practice seeks ways to minimize the impact of prostate cancer diagnosis and treatment on a man's health and quality of life.
“Dr. Sprenkle is an innovator dedicated to patient health and quality of life,” says Seker. “He is aware of the challenges involved in merging MRI images with ultrasound procedures, and is an advocate for minimally-invasive procedures for his patients. We’re thrilled to have his expertise on our clinical advisory team, and, on behalf of Board Chair Dean Mosca and the entire team, I’d like to welcome him to Insight Medbotics.”
Glenn™ is currently under development and is not approved by any regulatory body, nor is the system for sale in any international market.
